Amneal invests heavily in high-quality facilities, equipment, technology and talent to enable the seamless production of our portfolio of products.
A few of its more complex capabilities include long-acting depot technology for injectable products and microsphere/multiparticulate based development and scale-up. The company has mastered lyopholization, both at lab and commercial scales, as well as hot-melt extrusion and solid dispersion-based dosage forms, and continues to refine its processes across its manufacturing operations.
Amneal teams at every United States and India facility follow cGMP and operate in compliance with U.S. regulatory agencies, including FDA, EPA, OSHA and DEA. Similarly, all other international sites meet the standards set by their corresponding regulatory agencies.